New Perspective on the Treatment of Intractable Gastrointestinal Cancers: Role of Combination Therapies.

New Perspective on the Treatment of Intractable Gastrointestinal Cancers: Role of Combination Therapies. Keio J Med. 2017;66(4):72 Authors: Duda DG Abstract Unresectable gastrointestinal cancers, such as gastric, hepatocellular, biliary tract or pancreatic carcinomas, are often resistant to anti-cancer systemic therapies, and often recur locally or even after aggressive local therapies leading to dismal survival rates. Recent developments in oncology, have offered renewed hoped for the development of more efficacious therapies. For example, our understanding of the oncogenic drivers in carcinogenesis has increased exponentially, and may potentially allow personalization of therapy. In addition, a great interest has been recently to target immune checkpoints, and unleash the potential of the immune system against cancers. Finally, new radiation techniques (proton therapy) allow delivery of curative doses in a safely manner. However, optimal translation of these new therapeutic approaches will require a concerted effort in clinical trials and in preclinical studies. I will present results from clinical correlative studies and preclinical models of these diseases performed at our institution and in collaboration with other American and European investigators. The insights gained from this bench-to-the-bedside and back approach raise the hope for a more efficient development of targeted agents in gastrointestinal cancers, with the goal of increasing survival...
Source: The Keio Journal of Medicine - Category: Universities & Medical Training Authors: Tags: Keio J Med Source Type: research

Related Links:

Conclusions: In the treatment of intractable carcinomatous pain in patients with retroperitoneal lymph node metastases, CT-guided125 I brachytherapy is a feasible and effective modality for pain palliation.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Abstract Objectives: We aimed to evaluate the possible role of dietray TAC against different types of cancers in a systematic review and meta-analyses of observational studies. Methods: A literature search of authentic electronic resources had been performed to obtain the relevant studies up to February 2020. Results: Twenty-one studies including nine prospective and twelve case-control studies were included in the current systematic review and meta-analysis. These studies have included 1404297 individuals. Higher TAC categories were associated with 21% reduced risk of colorectal cancer, 27% reduced risk of endome...
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
Abstract Piperlongumine (PL), a herbal drug extracted from long pepper (Piper longum L), is known for its anti-inflammatory and anti-cancer properties. Although, its anti-cancer potential has been evaluated in cancer models like breast, pancreatic, gastric, hepatocellular and lung carcinoma, there is no report on its bio-activity evaluation in intestinal cancers. Here, we report the anti-neoplastic potential of PL against human intestinal carcinoma in-vitro and its possible mechanisms of action. Cytotoxicity studies demonstrate that PL inhibits cell proliferation of INT-407 and HCT-116 cells in a concentration and...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
This study assessed the patterns of opioid use among patients with advanced gastrointestinal cancers who were included in 8 clinical trials and evaluated the impact of opioid use on survival outcomes of included patients. METHODS: Deidentified datasets from 8 clinical trials evaluating first-line systemic treatment of advanced gastrointestinal cancers were accessed from the Project Data Sphere platform (ClinicalTrial.gov identifiers: NCT01124786, NCT00844649, NCT00290966, NCT00678535, NCT00699374, NCT00272051, NCT00305188, and NCT00384176). These trials evaluated patients with pancreatic carcinoma, gastric carcinoma, h...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Contributors : Ajay Goel ; Raju Kandimalla ; Wei Li ; Jianfeng XuSeries Type : Methylation profiling by high throughput sequencingOrganism : Homo sapiensOwing to high cancer-specificity, DNA methylation alterations have emerged as front-runners in cell-free DNA (cf-DNA) biomarker development. However, much effort to date has focused on single cancers and have not explored the possibility of developing a pan-cancer diagnostic assay. Here, we undertook a genome-wide DNA methylation analysis for multiple gastrointestinal (GI) cancers, to develop a panGI diagnostic assay. By analyzing the DNA methylation data from 1940 tumor a...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Methylation profiling by high throughput sequencing Homo sapiens Source Type: research
Authors: Mizrahi J, Pant S Abstract Gastrointestinal (GI) cancers represent a variety of malignancies, each with a unique interplay between the tumor and local immune microenvironment. The successes that immunotherapy, particularly immune checkpoint inhibition, has brought to various other solid tumors have largely not yielded the same benefits to patients with GI cancers. There are subsets of patients for whom immunotherapy has been FDA approved in recent years. For example, anti-PD-1 therapy is approved for patients with pretreated hepatocellular carcinoma. Additionally, patients with PD-L1-positive gastric cance...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Chen JM, Chiu SC, Chen KC, Huang YJ, Liao YA, Yu CR Abstract Enolase transforms 2-phospho-D-glycerate into phosphoenolpyruvate during glycolysis. The human enolase (ENO) family comprises three members named ENO3, which is restricted to muscle tissues, ENO2, which is neuron- and neuroendocrine tissue-specific, and ENO1, which is expressed in almost all tissues. ENO1 is involved in various types of human cancer, including retinoblastoma, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, cholangiocarcinoma and gastric cancer. Furthermore, ENO1 enhances cell transformation in numerous cancer c...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
ConclusionsHere, we discuss the role of ErbB4 in normal physiology and in breast, lung, colorectal, gastric, pancreatic, prostate, bladder, and brain cancers, as well as in hepatocellular carcinoma, cholangiocarcinoma, and melanoma. Understanding the role of ErbB4 in cancer is not only important for the treatment of tumors, but also for the treatment of other disorders in which ErbB4 plays a major role, e.g. cardiovascular disease.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
This study assesses survival improvement across a decade (2004 –2013) among patients with metastatic gastrointestinal cancers in a real-world setting.MethodsSurveillance, Epidemiology and End Results (SEER) database was accessed and patients with metastatic gastrointestinal carcinomas who have received any form of systemic therapy were included. Patients were grouped into three cohorts based on the year of diagnosis (cohort-1: 2004 –2006; cohort-2: 2008–2010; cohort-3: 2012–2013). Overall survival was compared among the three cohorts for each disease site using Kaplan-Meier survival estimates.Result...
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
Authors: Saif MW, Wasif K, Goodman MD, Hegde S, Sterling M, Yacavone R, Jaiswal S, Weinstein B, Daly K, Relias V Abstract Background: Carcinoma of unknown primary represents a therapeutic challenge in oncological practice. Evidence lacks to support particular chemotherapy selection and empirical therapies are commonly extrapolated from data on patients where primary tumor site is known. Gemcitabine, Oxaliplatin, Leucovorin and 5-Fluorouracil was previously developed to treat pancreatic cancer. These agents have also demonstrated activities in other gastrointestinal malignancies. Considering promising anti-tumor eff...
Source: Journal of the Pancreas - Category: Gastroenterology Tags: JOP Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Gastric (Stomach) Cancer | Gastroenterology | Hepatocellular Carcinoma | Liver Cancer | Pancreas | Pancreatic Cancer | Proton Therapy | Study | Universities & Medical Training